Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 26, 2019 16:01 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 2019 Cantor Global Healthcare Conference

NEW YORK, Sept. 26, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
September 18, 2019 09:32 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the Ladenburg Thalmann 2019 Healthcare Conference

NEW YORK, Sept. 18, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
September 05, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference

NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
August 09, 2019 16:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Present at the 2019 Wedbush PacGrow Healthcare Conference

NEW YORK, Aug. 09, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
August 08, 2019 22:23 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Pricing of $76,250,000 Public Offering of Common Stock

NEW YORK, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
August 07, 2019 16:25 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces Proposed Public Offering of Common Stock

NEW YORK, Aug. 07, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq:STML), a commercial -stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing...
August 06, 2019 07:30 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Announces that CMS Grants New Technology Add-on Payment (NTAP) to ELZONRIS®

NEW YORK, Aug. 06, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
August 02, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Reports Second Quarter 2019 Financial Results

Net revenue for ELZONRIS® was $13.0 million for the second quarterConference call and live webcast scheduled for today at 8:00 AM ET NEW YORK, Aug. 02, 2019 (GLOBE NEWSWIRE) -- Stemline...
July 29, 2019 07:00 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics to Host Conference Call on Second Quarter 2019 Financial Results on August 2, 2019

NEW YORK, July 29, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
July 08, 2019 17:50 ET | Source: Stemline Therapeutics, Inc.

Stemline Therapeutics Highlights Recent Clinical and Regulatory Developments and Details Upcoming Milestones following its Annual Shareholder Meeting

NEW YORK, July 08, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right